Last reviewed · How we verify
NGX267
At a glance
| Generic name | NGX267 |
|---|---|
| Sponsor | TorreyPines Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NGX267 CI brief — competitive landscape report
- NGX267 updates RSS · CI watch RSS
- TorreyPines Therapeutics portfolio CI